REGENXBIO Inc. (FRA:RB0)

REGENXBIO Statistics

Total Valuation

REGENXBIO has a market cap or net worth of EUR 548.68 million. The enterprise value is 519.52 million.

Market Cap	548.68M
Enterprise Value	519.52M

Important Dates

The next estimated earnings date is Tuesday, February 24, 2026.

Earnings Date	Feb 24, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	50.62M
Shares Outstanding	n/a
Shares Change (YoY)	+7.46%
Shares Change (QoQ)	+0.40%
Owned by Insiders (%)	7.94%
Owned by Institutions (%)	72.91%
Float	41.91M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.99
PB Ratio	3.99
P/TBV Ratio	3.99
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-3.43
EV / Sales	3.74
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-5.74

Financial Position

The company has a current ratio of 2.66, with a Debt / Equity ratio of 1.66.

Current Ratio	2.66
Quick Ratio	2.55
Debt / Equity	1.66
Debt / EBITDA	n/a
Debt / FCF	-2.52
Interest Coverage	-3.68

Financial Efficiency

Return on equity (ROE) is -76.88% and return on invested capital (ROIC) is -22.09%.

Return on Equity (ROE)	-76.88%
Return on Assets (ROA)	-18.54%
Return on Invested Capital (ROIC)	-22.09%
Return on Capital Employed (ROCE)	-38.67%
Revenue Per Employee	389,494
Profits Per Employee	-429,566
Employee Count	353
Asset Turnover	0.31
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +26.67% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+26.67%
50-Day Moving Average	9.80
200-Day Moving Average	7.87
Relative Strength Index (RSI)	62.62
Average Volume (20 Days)	160

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.22

Income Statement

In the last 12 months, REGENXBIO had revenue of EUR 137.49 million and -151.64 million in losses. Loss per share was -2.95.

Revenue	137.49M
Gross Profit	-66.85M
Operating Income	-132.05M
Pretax Income	-151.64M
Net Income	-151.64M
EBITDA	-118.61M
EBIT	-132.05M
Loss Per Share	-2.95

Balance Sheet

The company has 233.70 million in cash and 228.54 million in debt, giving a net cash position of 28.90 million.

Cash & Cash Equivalents	233.70M
Total Debt	228.54M
Net Cash	28.90M
Net Cash Per Share	n/a
Equity (Book Value)	137.61M
Book Value Per Share	2.72
Working Capital	176.77M

Cash Flow

In the last 12 months, operating cash flow was -88.04 million and capital expenditures -2.54 million, giving a free cash flow of -90.58 million.

Operating Cash Flow	-88.04M
Capital Expenditures	-2.54M
Free Cash Flow	-90.58M
FCF Per Share	n/a

Margins

Gross margin is -48.62%, with operating and profit margins of -96.04% and -110.29%.

Gross Margin	-48.62%
Operating Margin	-96.04%
Pretax Margin	-110.29%
Profit Margin	-110.29%
EBITDA Margin	-86.27%
EBIT Margin	-96.04%
FCF Margin	n/a

Dividends & Yields

REGENXBIO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.46%
Shareholder Yield	-7.46%
Earnings Yield	-27.64%
FCF Yield	-16.51%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

REGENXBIO has an Altman Z-Score of -2.31 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.31
Piotroski F-Score	3